The main purpose of this study is to assess the effect of multiple doses of itraconazole, fluconazole, and carbamazepine on single dose pharmacokinetic of LY4100511 (DICE-853) in healthy participants. The study will also evaluate the safety and tolerability of LY4100511 (DICE-853) with itraconazole, fluconazole, and carbamazepine.

Inclusion Criteria:

• Have a body mass index within the range of 18.0 to 32 kilograms per square meter (kg/m²)
• Males who agree to follow contraceptive requirements and women of not childbearing potential
• Have body weight greater than or equal to (>=) 50 Kilograms at screening.
• Must have a negative Interferon-Gamma Release Assays (IGRA) testing at screening
• Must have been stopped all the prescribed medication at least 14 days prior to admission to the clinical site
• Ability and willingness to abstain from alcohol, caffeine, and methylxanthine-containing beverages or food 2 days prior to admission to the clinical site
• Abstain from any strenuous physical exercise from 4 days prior to admission and during confinement at the clinical site

Exclusion Criteria:

• Have a history of relevant drug and/or food allergies, or sensitivity to medications used in the current study
• Females participants who are currently breastfeeding
• Have History of alcohol abuse or drug addiction
• Unable to abstain from tobacco products within the 2 days prior to admission and during confinement at the clinical site
• Have Positive screen for hepatitis B surface antigen, hepatitis C virus (HCV) antibodies, or human immunodeficiency virus (HIV) 1 and 2 antibodies
• Consumption of any nutrients known to modulate CYP450 enzymes activity
• Are immunocompromised
• Have received live vaccine(s) (including attenuated live vaccines) or Bacillus Calmette-Guérin within 28 days of screening or intend to receive them during the study
• Have had any malignancy within the past 5 years